+++
title = "Psychedelikum"
description = "Psychedelika - latky menici vedomi, vyvolavajici zmenene stavy vnimani, mysleni a emoci prostrednictvim agonismu na 5-HT2A receptorech"
weight = 2
insert_anchor_links = "right"

[taxonomies]
categories = ["neurofarmakologie", "psychoaktivni-latky"]
tags = ["psychedelika", "halucinogeny", "5-HT2A", "serotonin", "tryptaminy", "fenethylaminy", "ergoliny", "terapie"]
+++

# Psychedelikum - Latky menici vedomi

**Psychedelika** (z reckeho *psyche* = duse, *delein* = zjevovat, manifestovat) jsou tridou psychoaktivnich latek, ktere vyvolavaji **zmenene stavy vedomi** charakterizovane zmenami vnimani, mysleni a emoci. Termin zavedl britsky psychiatr **Humphry Osmond** v roce 1957 v korespondenci s Aldousem Huxleym.

Psychedelika pusobi primarne jako agoniste [5-HT2A receptoru](/receptors/5-ht2a/) a predstavuji jednu z nejintenzivneji zkoumanycch skupin latek v modernni neurovede a psychiatrii.

---

## Definice a etymologie

### Puvod terminu

| Aspekt | Detail |
|--------|--------|
| **Termin** | Psychedelic (anglicky), psychedelikum (cesky) |
| **Etymologie** | Recky: *psyche* (duse) + *delein* (zjevovat) |
| **Vyznam** | "Zjevujici dusi" / "Manifestujici mysl" |
| **Autor** | Humphry Osmond (1917-2004) |
| **Rok zavedeni** | 1957 |
| **Kontext** | Korespondence s Aldousem Huxleym |

### Osmondova definice (1957)

Humphry Osmond navrhl termin v dopise Aldousu Huxleymu:

> *"To fathom Hell or soar angelic, just take a pinch of psychedelic."*
> ("Abyste pronikli do pekla nebo vzleteli k andelum, staci spetka psychedelika.")

Osmond hledal neutralni termin, ktery by nahradil pejorativni oznaceni jako "halucinogeny" nebo "psychotomimetika" (latky napodobujici psychozu).

### Historicka terminologie

| Termin | Obdobi | Problem |
|--------|--------|---------|
| **Phantastica** | 1920s | Prilis vseobecny |
| **Psychotomimetika** | 1950s | Implikuje patologii |
| **Halucinogeny** | 1950s | Nepresny (prave halucinace vzacne) |
| **Psycholytika** | 1960s | Pouzivano v psychoterapii |
| **Entheogeny** | 1979 | Nabozensky kontext |
| **Psychedelika** | 1957+ | Neutralni, vedecky preferovany |

### Soucasne vymezeni

Psychedelika jsou definovana:

1. **Farmakologicky**: Agoniste 5-HT2A receptoru
2. **Fenomenologicky**: Zmenene stavy vedomi bez sedace
3. **Bezpecnostne**: Minimalni fyzicka toxicita, nulovy zavislostni potencial
4. **Funkcne**: Zvysena neuroplasticita a "entropic brain state"

---

## Chemicka klasifikace

Psychedelika se klasifikuji podle chemicke struktury do tri hlavnich trid:

### 1. Tryptaminy

Odvozeny od tryptaminu (indol + ethylamin). Strukturne pribuzne serotoninu.

```
TRYPTAMINOVY SCAFFOLD:
                    R4
                     |
                5    4
                 \  /
              6   \/
               \  ||
                \/  \3
                ||   |
                 \  /\
              7   \/  N--R1
               \  |   |
                \ |   R2
                 \|
                  N
                  |
                  H

R1, R2 = substituenty na dusiku (methylace)
R4 = substituent na indolovem kruhu (OH, OPO3, OCH3)
```

| Alkaloid | Struktura | Primarni zdroj | Dokumentace |
|----------|-----------|----------------|-------------|
| [**Psilocybin**](/alkaloids/psilocybin/) | 4-PO-DMT (prodrug) | [Psilocybe houby](/shrooms/psilocybes/) | Kompletni |
| [**Psilocin**](/alkaloids/psilocin/) | 4-HO-DMT | [Psilocybe houby](/shrooms/psilocybes/) | Kompletni |
| [**DMT**](/alkaloids/dmt/) | N,N-DMT | Ayahuasca, endogenni | Kompletni |
| [**Baeocystin**](/alkaloids/baeocystin/) | 4-PO-NMT | [Psilocybe houby](/shrooms/psilocybes/) | Kompletni |
| **5-MeO-DMT** | 5-methoxy-DMT | Bufo alvarius | - |
| **Bufotenin** | 5-HO-DMT | Anadenanthera | - |

### 2. Fenethylaminy

Odvozeny od fenethylaminu (benzen + ethylamin). Strukturne pribuzne dopaminu.

```
FENETHYLAMINOVY SCAFFOLD:
        R3
         |
    +----+----+
   /     |     \
  |   R4        |
  |      \      |
   \      +----/
    \    /
     \  /
      \/
       |
       CH2
       |
       CH2
       |
       NH2

R3, R4, R5 = substituenty na benzenovem kruhu (methoxy, halogeny)
```

| Latka | Struktura | Zdroj | Dokumentace |
|-------|-----------|-------|-------------|
| [**Meskalin**](/alkaloids/mescaline/) | 3,4,5-trimethoxy-PEA | Peyotl, San Pedro | Kompletni |
| **2C-B** | 4-bromo-2,5-dimethoxy-PEA | Synteticky | - |
| **2C-E** | 4-ethyl-2,5-dimethoxy-PEA | Synteticky | - |
| **DOM** | 2,5-dimethoxy-4-methyl-amfetamin | Synteticky | - |
| **DOI** | 2,5-dimethoxy-4-iodo-amfetamin | Vyzkumny nastroj | - |

### 3. Ergoliny (Lysergamidy)

Komplexni tetracyklicka struktura odvozena od kyseliny lysergove.

```
ERGOLINOVY SCAFFOLD:
                    O
                    ||
            H3C-CH2-N-CH2-CH3
                    |
                    C=O
                    |
              [9]---C---H
             /           \
           [8]            [10]
            |     N-CH3    |
           [7]----[6a]----[4]
            |       |       |
           [6]     [5]     [3]
            \       |      /
             \     [4a]   /
              \     |    /
               [11]-[11a]
                 \   |
                  \ /
                  [2]
                   |
                  N-H
```

| Latka | Typ | Zdroj | Dokumentace |
|-------|-----|-------|-------------|
| [**LSD**](/alkaloids/lsd/) | Diethylamid | Semisynteticky | Kompletni |
| **1P-LSD** | 1-propionyl-LSD | Synteticky (prodrug) | - |
| **ALD-52** | 1-acetyl-LSD | Synteticky (prodrug) | - |
| **LSA** | Amid kyseliny lysergove | Convolvulaceae | - |
| **ETH-LAD** | 6-ethyl-nor-LSD | Synteticky | - |

### Srovnani strukturnich trid

| Vlastnost | Tryptaminy | Fenethylaminy | Ergoliny |
|-----------|------------|---------------|----------|
| **Zakladni struktura** | Indol | Benzen | Tetracykl |
| **Podobnost k 5-HT** | Vysoka | Nizka | Stredni |
| **5-HT2A afinita** | Vysoka | Nizka-stredni | Velmi vysoka |
| **Metabolismus** | MAO-A | Hepatalni | CYP3A4 |
| **Typicke trvani** | 4-6 h | 8-12 h | 8-12 h |
| **Typicka potence** | mg | stovky mg | mikrogramy |

---

## Mechanismus ucinku

### Primarni cil: 5-HT2A receptor

Vsechna klasicka psychedelika pusobi jako agoniste [5-HT2A receptoru](/receptors/5-ht2a/):

```
PSYCHEDELIKUM
      |
      v
5-HT2A receptor (vrstva V kortexu)
      |
      v
Gq/11 protein aktivace
      |
      +----------------+
      |                |
      v                v
Fosfolipaza C      beta-arrestin
      |                |
      v                |
IP3 + DAG              v
      |           Internalizace
      v
Ca2+ release + PKC aktivace
      |
      v
ERK1/2 -> CREB -> BDNF
      |
      v
NEUROPLASTICITA
```

### Receptorove profily klasickych psychedelik

| Latka | 5-HT2A Ki (nM) | 5-HT2C Ki | 5-HT1A Ki | D2 Ki |
|-------|----------------|-----------|-----------|-------|
| [LSD](/alkaloids/lsd/) | **1-2** | 5-10 | 2-10 | 10-50 |
| [Psilocin](/alkaloids/psilocin/) | 6-15 | 30-100 | 50-200 | >1000 |
| [DMT](/alkaloids/dmt/) | 75-130 | 360 | >1000 | >10000 |
| [Meskalin](/alkaloids/mescaline/) | 5000+ | 2000+ | >10000 | >10000 |

**Poznamka**: Ki = inhibicni konstanta. Nizsi hodnota = vyssi afinita.

### Funkcionalni selektivita (Biased agonism)

Ruzna psychedelika aktivuji ruzne signalni drahy:

| Ligand | Gq/11 signalizace | beta-arrestin | Head-Twitch Response |
|--------|-------------------|---------------|---------------------|
| Serotonin | +++ | +++ | - |
| [LSD](/alkaloids/lsd/) | +++ | + | +++ |
| [Psilocin](/alkaloids/psilocin/) | ++ | ++ | ++ |
| DOI | +++ | ++ | +++ |
| Lisurid | + | ++ | - (bez halucinaci) |

### "Lid" hypoteza (LSD)

Krystalograficka studie Wacker et al. (2017) ukazala, ze LSD je "uvezeno" v receptoru:

```
Extracelularni smycka 2 (EL2) se zavira nad LSD
           |
           v
Prodlouzeny rezidencni cas v receptoru
           |
           v
Vysvetluje 8-12 hodin trvani ucinku
```

### Neuronalni efekty

| Efekt | Mechanismus | Subjektivni korelat |
|-------|-------------|---------------------|
| Depolarizace pyramidovych neuronu | 5-HT2A ve vrstve V | Zmeny vnimani |
| Suprese Default Mode Network | Snizena konektivita | Ego-dissolution |
| Zvysena entropie mozku | Narusa hierarchii | Kreativita, insight |
| Zvysena globalni konektivita | Nove neuronalni spoje | Synesteze |
| Neuroplasticita | BDNF indukce | Dlouhodobe zmeny |

---

## Klasicka vs. atypicka psychedelika

### Klasicka (serotonergni) psychedelika

**Definice**: Latky pusobici primarne prostrednictvim 5-HT2A agonismu.

| Latka | Trida | Potence | Trvani |
|-------|-------|---------|--------|
| [LSD](/alkaloids/lsd/) | Ergolin | Velmi vysoka | 8-12 h |
| [Psilocybin](/alkaloids/psilocybin/) | Tryptamin | Stredni | 4-6 h |
| [DMT](/alkaloids/dmt/) | Tryptamin | Stredni | 15-60 min |
| [Meskalin](/alkaloids/mescaline/) | Fenethylamin | Nizka | 8-12 h |

**Charakteristiky**:
- 5-HT2A primarne
- Vizualni a kognitivni efekty
- Minimalni fyzicka toxicita
- Zadny zavislostni potencial
- Rychla tolerance (dny)
- Krizova tolerance mezi sebou

### Atypicka psychedelika

Latky s psychedelickymi efekty, ale odlisnym primarnim mechanismem:

| Latka | Primarni receptor | Typ | Dokumentace |
|-------|-------------------|-----|-------------|
| [Muscimol](/alkaloids/muscimol/) | [GABA-A](/receptors/gaba-a/) | Deliriant/Disociativ | [Muscimol](/alkaloids/muscimol/) |
| Ibogain | Kappa-opioid, NMDA | Oneirogen | - |
| Salvinorin A | Kappa-opioid | Disociativ | - |
| Ketamin | [NMDA](/receptors/nmda/) | Disociativ | - |
| MDMA | SERT, NET, DAT | Entaktogen | - |

### Srovnani klasickych a atypickych

| Aspekt | Klasicka | Atypicka |
|--------|----------|----------|
| **Primarni receptor** | 5-HT2A | Ruzne (GABA, NMDA, kappa) |
| **Vizualni efekty** | Komplexni geometrie | Variabilni |
| **Vedomi** | Zachovano | Casto naruseno |
| **Amneze** | Ne | Casto ano |
| **Fyzicka rizika** | Minimalni | Variabilni (vyssi u nekterych) |
| **Terapeuticky vyzkum** | Intenzivni | Limitovany |

---

## Set a Setting

Koncept "set and setting" zavedl Timothy Leary v 1960s a zustal fundamentalni pro bezpecne uzivani psychedelik.

### Set (Mindset)

Vnitrni stav uzivatele pred a behem zkusenosti:

| Faktor | Popis | Doporuceni |
|--------|-------|------------|
| **Nalada** | Aktualni emocni stav | Stabilni, pozitivni |
| **Ocekavani** | Predstavy o zkusenosti | Realisticka, otevrena |
| **Umysl** | Cil zkusenosti | Jasne definovany |
| **Pripravenost** | Mentalni priprava | Bez stresu, ukolu |
| **Zkusenost** | Predchozi expozice | Zacit s nizsi davkou |
| **Psychicke zdravi** | Aktualni stav | Bez akutnich problemu |

### Setting (Prostredi)

Externi podminky zkusenosti:

| Faktor | Popis | Doporuceni |
|--------|-------|------------|
| **Misto** | Fyzicke prostredi | Bezpecne, zname, pohodlne |
| **Lide** | Pritomni ostatni | Duveryhodní, nebo soliterni |
| **Sitter** | Strizlivy pruvodce | Doporucen pro zacatecniky |
| **Hudba** | Zvukove prostredi | Bez textu, ambient, klasika |
| **Svetlo** | Osvetleni | Regulovatelne, tlumene |
| **Teplota** | Teplotni komfort | Prijemna, prikryvky k dispozici |
| **Cas** | Casove podminky | Dostatek casu, volny nasledujici den |

### Harm Reduction principy

1. **Testuj latku** - Ehrlich/Hofmann reagenty
2. **Zacni nizko** - Prvni zkusenost s nizsi davkou
3. **Mel sitttera** - Strizliva duveryhodna osoba
4. **Bezpecny prostor** - Zadna rizika (ostriny, vysky, voda)
5. **Hydratace** - Dostatek vody
6. **Integrace** - Cas na zpracovani zkusenosti
7. **"Kill switch"** - Benzodiazepiny ukoncuji trip
8. **Zadna rizda** - Minimalne 24 hodin

---

## Terapeuticky potencial

### Soucasne klinicke studie

| Indikace | Latka | Faze | Status | Vedouci instituce |
|----------|-------|------|--------|-------------------|
| **Rezistentni deprese** | Psilocybin | III | Pokracuje | COMPASS Pathways |
| **MDD** | Psilocybin | II | Dokoncena | Usona Institute |
| **PTSD** | Psilocybin | II | Pokracuje | MAPS |
| **Alkoholismus** | Psilocybin | II | Pozitivni | NYU, Johns Hopkins |
| **Nikotinismus** | Psilocybin | II/III | Pokracuje | Johns Hopkins |
| **Uzkost (terminalni)** | Psilocybin | II | Pozitivni | NYU, Johns Hopkins |
| **OCD** | Psilocybin | II | Nabor | Yale |
| **GAD** | LSD | II/III | Pokracuje | MindMed |
| **Cluster headache** | Psilocybin | II | Pokracuje | Yale/MAPS |

### Mechanismy terapeutickeho efektu

```
1. NEUROPLASTICITA
   Psychedelikum --> 5-HT2A --> BDNF uvolneni --> Synaptogeneze

2. DMN RESET
   Psychedelikum --> Snizena DMN aktivita --> Preruseni ruminace

3. EMOCIONALNI PRULOM
   Psychedelikum --> Snizena amygdala reaktivita --> Zpracovani traumatu

4. MYSTICKY ZAZITEK
   Psychedelikum --> Ego dissolution --> Existencialni insight

5. PSYCHEDELICKA PSYCHOTERAPIE
   Psychedelikum + terapie --> Zrychleny terapeuticky proces
```

### Vysledky klicovych studii

| Studie | N | Indikace | Vysledek |
|--------|---|----------|----------|
| COMPASS Phase IIb (2022) | 233 | TRD | 29% remise (25mg) |
| Carhart-Harris et al. (2021) | 59 | MDD | Psilocybin >= escitalopram |
| Bogenschutz et al. (2022) | 95 | Alkoholismus | 83% redukce piti |
| Johnson et al. (2014) | 15 | Nikotinismus | 80% abstinence 6 mesicu |
| Griffiths et al. (2016) | 51 | Uzkost (rakovina) | 80% zlepseni |

### FDA Breakthrough Therapy Designation

| Rok | Indikace | Sponzor |
|-----|----------|---------|
| 2018 | Treatment-resistant depression | COMPASS Pathways |
| 2019 | Major depressive disorder | Usona Institute |

---

## Historie psychedelik

### Prehistorie a tradicni uzivani

| Obdobi | Latka | Region | Kontext |
|--------|-------|--------|---------|
| ~5700 pr.n.l. | Peyotl | Texas/Mexiko | Nejstarsi dukazy |
| ~3000 pr.n.l. | San Pedro | Peru | Ceremonalni uziti |
| ~1000 pr.n.l. | Ayahuasca | Amazonie | Samanske ritualy |
| ~500 pr.n.l. | Psilocybe houby | Mezoamerika | "Teonanacatl" |

### Vedecky objev (1897-1960)

| Rok | Udalost | Osoba/Instituce |
|-----|---------|-----------------|
| **1897** | Izolace meskalinu | Arthur Heffter |
| **1919** | Synteza meskalinu | Ernst Spath |
| **1938** | Synteza LSD-25 | Albert Hofmann, Sandoz |
| **1943** | Objev psychoaktivity LSD | Albert Hofmann ("Bicycle Day") |
| **1947** | Sandoz uvadi Delysid | Sandoz Laboratories |
| **1952** | Meskalin a Huxley | Humphry Osmond |
| **1954** | "The Doors of Perception" | Aldous Huxley |
| **1957** | Izolace psilocybinu | Albert Hofmann |
| **1957** | Termin "psychedelic" | Humphry Osmond |

### Klicove osobnosti

#### Albert Hofmann (1906-2008)

Svycasky chemik, "otec LSD":

| Rok | Prinos |
|-----|--------|
| 1938 | Synteza LSD-25 |
| 1943 | Objev psychoaktivity (Bicycle Day, 19. dubna) |
| 1957 | Izolace psilocybinu a psilocinu |
| 1979 | "LSD: My Problem Child" |

> *"Veril jsem, ze pokud lide budou mit psychedelickou zkusenost... pochopi, ze jsme vsichni casti jednoho celku."*

#### Alexander Shulgin (1925-2014)

Americky chemik, "krestni otec psychedelik":

| Rok | Prinos |
|-----|--------|
| 1976 | Znovuobjeveni MDMA |
| 1991 | PiHKAL (Phenethylamines I Have Known And Loved) |
| 1997 | TiHKAL (Tryptamines I Have Known And Loved) |
| - | Synteza a dokumentace 200+ psychoaktivnich latek |

> *"Zasluhuji si pravo vedet, co me vlastni telo a mysl delaji."*

#### Timothy Leary (1920-1996)

Americky psycholog, kontroverzni propagator:

| Rok | Udalost |
|-----|---------|
| 1960 | Harvard Psilocybin Project |
| 1963 | Vyhozeni z Harvardu |
| 1966 | "Turn on, tune in, drop out" |
| 1970 | Vezeni za drzeni marihuany |

**Poznamka**: Learyho pristup je dnes viden jako kontraproduktivni pro vyzkum.

### Zlata era a prohibice (1960-1970)

| Rok | Udalost |
|-----|---------|
| **1960-1965** | >1000 publikaci o psychedelikach |
| **1962** | Kongres USA omezuje vyzkum |
| **1966** | Zakaz v Kalifornii a nasledne v USA |
| **1970** | Controlled Substances Act - Schedule I |
| **1971** | UN Convention on Psychotropic Substances |

### Renesance (2000-soucasnost)

| Rok | Udalost |
|-----|---------|
| 2006 | Griffiths - psilocybin a mysticke zazitky (Johns Hopkins) |
| 2011 | Carhart-Harris - fMRI psilocybin (Imperial College) |
| 2016 | Carhart-Harris - LSD neuroimaging |
| 2017 | Wacker - krystalova struktura LSD-5-HT2A |
| 2018 | FDA Breakthrough Therapy pro psilocybin |
| 2020 | Oregon - legalizace psilocybinu pro terapii |
| 2022 | Colorado - dekriminalizace psychedelik |
| 2023 | Australie - lekarske pouziti psilocybinu a MDMA |

---

## Fenomenologie psychedelickeho zazitku

### Faze tripu

| Faze | Cas (psilocybin) | Charakteristika |
|------|------------------|-----------------|
| **Latence** | 0-30 min | Ocekavani, mirna uzkost |
| **Come-up** | 30-90 min | Nastup efektu, telesne pocity |
| **Peak** | 90-180 min | Maximum intenzity |
| **Plateau** | 180-300 min | Stabilni efekty |
| **Come-down** | 300-360 min | Postupne odeznivani |
| **Afterglow** | 6-24 h | Rezidualni pozitivni nalada |

### Vizualni efekty (taxonomie)

| Uroven | Typ | Popis |
|--------|-----|-------|
| 1 | Zvysena ostrost | Zivejsi barvy, ostreji kontury |
| 2 | Drifting | Povrchy se "hybi" |
| 3 | Breathing | Objekty "dychaji" |
| 4 | Morphing | Tvary se meni |
| 5 | Tracers | Stopy za pohybem |
| 6 | Geometrie (OEV) | Vzory na objektech |
| 7 | Geometrie (CEV) | Fraktaly, mandaly (zavrene oci) |
| 8 | Synesteze | Videni zvuku |
| 9 | Halucinace | Komplexni obrazy |
| 10 | Breakthrough | Kompletni zmena reality |

### Kognitivni efekty

| Efekt | Frekvence | Popis |
|-------|-----------|-------|
| **Introspekce** | Velmi caste | Hluboke sebepoznani |
| **Kreativita** | Caste | Nove spojeni myslenek |
| **Casova distorze** | Velmi caste | Minuty jako hodiny |
| **Thought loops** | Obcas | Opakujici se myslenkove vzorce |
| **Ego dissolution** | Pri vyssich davkach | Rozpusteni hranic ja |
| **Mysticke zazitky** | Pri vyssich davkach | Jednota, transcendence |
| **Noeticky insight** | Caste | Pocit "poznani pravdy" |

### Entropic Brain Hypothesis

```
ENTROPIE MOZKOVE AKTIVITY

Nizka entropie                    Vysoka entropie
(rigidni, prediktabilni)          (flexibilni, variabilni)
        |                                |
        v                                v
+------------------+             +------------------+
|  - Deprese       |             |  - Psychedelicky |
|  - OCD           |             |    stav          |
|  - Zavislosti    | PSYCHEDELIKA|  - Kreativita    |
|  - Rigidni       | ==========> |  - Flexibilita   |
|    mysleni       |             |  - Insight       |
+------------------+             +------------------+

Terapeuticky potencial:
Docasne zvyseni entropie --> Reset rigidnich vzorcu
```

---

## Bezpecnostni profil

### Fyziologicka toxicita

| Latka | LD50 (mg/kg)* | Bezpecnostni pomer | Letalni davka clovek |
|-------|---------------|-------------------|---------------------|
| [LSD](/alkaloids/lsd/) | 0.3 (i.v., kralik) | >1000 | Teoreticky >10 mg |
| [Psilocybin](/alkaloids/psilocybin/) | 280 (i.v., mys) | >1000 | Teoreticky >17 g |
| [DMT](/alkaloids/dmt/) | >50 | >100 | Neznama |
| [Meskalin](/alkaloids/mescaline/) | 212 (i.p., mys) | >10 | Neznama |

*LD50 hodnoty z zvirecich studii

**Poznamka**: Zadna potvrzena smrt z predavkovani samotnym LSD nebo psilocybinem.

### Psychologicka rizika

| Riziko | Frekvence | Rizikove faktory |
|--------|-----------|------------------|
| **Bad trip** | 10-25% | Set/setting, vysoka davka |
| **Prolongovana uzkost** | <5% | Predchozí uzkostne poruchy |
| **HPPD** | <1% | Opakované vysoké dávky |
| **Psychoza** | <0.1% | Osobni/rodinná anamneza |
| **Flashbacky** | 5-10% | Vetsinou benigni |

### Kontraindikace

| Absolutni | Relativni |
|-----------|-----------|
| Schizofrenie | Uzkostne poruchy |
| Psychoza v anamneze | Tezka deprese |
| Bipolarni porucha I | Kardiovaskularni choroby |
| Psychoza u pribuznych 1. rade | SSRI (snizeny ucinek) |
| Lithium (riziko zauchvatu) | Epilepsie |
| Tehotenstvi | - |

### Lekove interakce

| Lecivo | Interakce | Doporuceni |
|--------|-----------|------------|
| **SSRI** | Snizeny ucinek | Vysadit 2 tydny pred |
| **MAOi** | Potenciace (DMT) | Specificke protokoly |
| **Lithium** | Riziko zauchvatu | Absolutne kontraindikováno |
| **Tramadol** | Serotonin syndrom | Kontraindikovano |
| **Benzodiazepiny** | Snizeny ucinek | Rescue medication |
| **Antipsychotika** | Blokada ucinku | Kontraindikovano |

---

## Pravni status

### Mezinarodni klasifikace

| Jurisdikce | LSD | Psilocybin | DMT | Meskalin |
|------------|-----|------------|-----|----------|
| **OSN (1971)** | Schedule I | Schedule I | Schedule I | Schedule I |
| **USA** | Schedule I | Schedule I* | Schedule I | Schedule I |
| **EU** | Zakazano | Zakazano | Zakazano | Zakazano |
| **Ceska republika** | Zakazano | Zakazano | Zakazano | Zakazano |

*Vyjimky: Oregon (terapie), Colorado (dekriminalizace)

### Ceska republika

| Aspekt | Detail |
|--------|--------|
| **Legislativa** | Narizeni vlady c. 463/2013 Sb. |
| **Kategorie** | Tabulka c. 1 - zakazane latky |
| **Tresty - drzeni** | Az 1-5 let |
| **Tresty - distribuce** | 2-10 let |
| **Vyjimka** | Vedecky vyzkum s povolenim |

### Trendy v legalizaci

| Rok | Jurisdikce | Zmena |
|-----|------------|-------|
| 2019 | Denver, CO | Dekriminalizace psilocybinu |
| 2020 | Oregon | Legalizace pro terapii (Measure 109) |
| 2020 | Washington, DC | Dekriminalizace enthogenu |
| 2022 | Colorado | Dekriminalizace psychedelik |
| 2023 | Australie | Lekarske pouziti psilocybinu a MDMA |

---

## Srovnani s ostatnimi psychoaktivnimi tridy

| Trida | Primarni receptor | Zavislost | Toxicita | Terapeuticky potencial |
|-------|-------------------|-----------|----------|------------------------|
| **Psychedelika** | 5-HT2A | Zadny | Velmi nizka | Vysoky |
| Stimulanty | DAT, NET | Vysoky | Stredni | Nizky |
| Opiaty | Mu-opioid | Velmi vysoky | Vysoka | Omezeny |
| Sedativa | GABA-A | Stredni | Stredni | Omezeny |
| Kanabinoidy | CB1, CB2 | Nizky | Nizka | Stredni |
| Disociativa | NMDA | Nizky-stredni | Stredni | Zkoumanv |

---

## Kulturni a filozoficky vyznam

### Vliv na umeni a kulturu

| Oblast | Priklad vlivu |
|--------|---------------|
| **Hudba** | The Beatles, Grateful Dead, Pink Floyd |
| **Vizualni umeni** | Alex Grey, psychedelicky plakat |
| **Literatura** | Aldous Huxley, Ken Kesey |
| **Film** | 2001: Vesmirna odysea, Fear and Loathing |
| **Veda** | Francis Crick (DNA), Kary Mullis (PCR) |

### Filozoficke otazky

1. **Ontologie**: Jaky je status psychedelickych zkusenosti? Jsou "realne"?
2. **Epistemologie**: Je "noeticky insight" legitimni forma poznani?
3. **Etika**: Je psychedelicka zkusenost "hodnotna sama o sobe"?
4. **Vedomi**: Co nam psychedelika rikaji o povaze vedomi?

---

## Reference

### Zakladni literatura

1. Hofmann, A. (1979). *LSD: My Problem Child*. McGraw-Hill.
2. Shulgin, A. & Shulgin, A. (1991). *PiHKAL: A Chemical Love Story*. Transform Press.
3. Shulgin, A. & Shulgin, A. (1997). *TiHKAL: The Continuation*. Transform Press.
4. Strassman, R. (2001). *DMT: The Spirit Molecule*. Park Street Press.
5. Pollan, M. (2018). *How to Change Your Mind*. Penguin Press.

### Vedecke prehledove clanky

6. Nichols, D.E. (2016). *Psychedelics*. Pharmacological Reviews, 68(2), 264-355.
7. Vollenweider, F.X. & Preller, K.H. (2020). *Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders*. Nature Reviews Neuroscience, 21(11), 611-624.
8. Carhart-Harris, R.L. & Friston, K.J. (2019). *REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics*. Pharmacological Reviews, 71(3), 316-344.

### Klinicke studie

9. Griffiths, R.R. et al. (2016). *Psilocybin produces substantial and sustained decreases in depression and anxiety*. Journal of Psychopharmacology.
10. Carhart-Harris, R.L. et al. (2021). *Trial of psilocybin versus escitalopram for depression*. NEJM.
11. Bogenschutz, M.P. et al. (2022). *Psilocybin-assisted treatment for alcohol use disorder*. JAMA Psychiatry.

### Neuroimaging

12. Carhart-Harris, R.L. et al. (2016). *Neural correlates of the LSD experience revealed by multimodal neuroimaging*. PNAS.
13. Wacker, D. et al. (2017). *Crystal Structure of an LSD-Bound Human Serotonin Receptor*. Cell.

---

## Souvisejici stranky

### Alkaloidy (psychedelika)

- [Psilocybin](/alkaloids/psilocybin/) - Houbove psychedelikum
- [Psilocin](/alkaloids/psilocin/) - Aktivni metabolit psilocybinu
- [LSD](/alkaloids/lsd/) - Nejpotentnejsi psychedelikum
- [DMT](/alkaloids/dmt/) - "Spirit Molecule"
- [Meskalin](/alkaloids/mescaline/) - Kaktusove psychedelikum
- [Baeocystin](/alkaloids/baeocystin/) - Minor houbovy alkaloid

### Houby

- [Psilocybes](/shrooms/psilocybes/) - Psychedelicke houby
- [Psilocybe cubensis](/shrooms/psilocybes/cubensis/) - Nejbeznejsi druh
- [Psilocybe semilanceata](/shrooms/psilocybes/semilanceata/) - Evropsky druh
- [Psilocybe bohemica](/shrooms/psilocybes/bohemica/) - Cesky druh

### Receptory

- [5-HT2A receptor](/receptors/5-ht2a/) - Primarni cil psychedelik
- [GABA-A receptor](/receptors/gaba-a/) - Cil atypickych psychedelik
- [NMDA receptor](/receptors/nmda/) - Cil disociativ

### Ostatni

- [Alkaloidy](/alkaloids/) - Prehled vsech alkaloidu
- [Glosar](/glossary/) - Definice pojmu
- [GABA](/glossary/gaba/) - Inhibicni neurotransmiter
- [Receptor](/glossary/receptor/) - Obecny pojem

---

<- Zpet na [Glosar](/glossary/) | [GABA](/glossary/gaba/) | [Receptor](/glossary/receptor/) ->

---

*Tato stranka slouzi pouze pro edukacni a harm reduction ucely. Psychedelika jsou v Ceske republice nezakonne latky. Vsechny informace jsou zalozeny na vedecke literature.*

---

*Posledni aktualizace: 2026-01-30*
